Compare

ALK-Abelló A/S/DKr ALK B

1D1W1M3M6MYTD1Y5YMAX

About ALK-Abelló A/S

ALK-Abelló A/S is a pharmaceutical company engaged in the development and production of allergy immunotherapy products. Based in Hørsholm, Denmark, the company specializes in allergy treatments that include tablets, injections, and drops targeting common allergens such as grass, tree, and ragweed pollen, as well as house dust mites. Established in the early 20th century, ALK-Abelló has expanded its operations to serve markets globally, with a particular focus on Europe and North America. Its strategic advantage lies in its strong research capabilities and a comprehensive portfolio of allergy treatment options. The company's ongoing investment in innovation supports its goal to transform the treatment of allergies worldwide.
Ticker
DKr ALK B
Sector
Health
Primary listing
CSE
Employees
2,773
Headquarters
Horsholm, Denmark
Website
www.alk.net

ALK-Abelló A/S Metrics

BasicAdvanced
kr 55B
40.60
kr 6.10
0.71
kr 1.60
0.65%

Bulls say / Bears say

ALK raised its 2026 revenue-growth outlook to 16–17% and its EBIT-margin target to around 27%, citing strong tablet sales and operating leverage. The higher guidance points to momentum translating into stronger earnings. (Inderes)
Q2 revenue grew 18% and tablet sales rose 22%, with double-digit growth across regions; first-half EBIT margin reached 28%. This broad growth and solid profitability support the case that ALK’s current products are scaling well. (GlobeNewswire)
ALK has begun expanding neffy into Canada and European markets, while UK recommendations support paediatric access to two allergy tablets. These launches and access gains could add growth beyond the established tablet franchise. (GlobeNewswire)
In Q2, the EBIT margin stayed at 25% despite higher sales, as investment in sales and marketing offset gross-margin improvements. Continued spending on launches and research could limit how much of the revenue growth reaches operating profit. (GlobeNewswire)
Management discussed a higher German rebate taking effect in 2027 and plans to rebalance existing agreements. If those measures do not fully offset the change, pricing and margins could come under pressure. (Roic AI)
The peanut-allergy tablet remains a development-stage opportunity: the Phase 3 trial is only expected to start in late 2026, with regulatory discussions still under way. Delays or an unsuccessful trial would defer a potential new source of growth. (GlobeNewswire)
Data summarised monthly by Lightyear AI. Last updated on 8 Oct 2026.

Funds containing ALK-Abelló A/S

AllUSDEUR
Funds
Fund name
Fund size
DKr ALK B weighting
Xtrackers MSCI Europe Small Cap£XXSC
$3.6B0.28%
Xtrackers MSCI Europe Small Cap€DX2J
$3.6B0.28%
iShares STOXX Europe 600 Health Care€EXV4
€709M0.24%
iShares MSCI World Small Cap£WLDS
$9B0.04%
iShares MSCI World Small Cap$WSML
$9B0.04%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.